• Users Online: 298
  • Home
  • Print this page
  • Email this page
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
This article has been cited by
1Tofacitinib or adalimumab versus placebo: patient-reported outcomes from OPAL Broaden—a phase III study of active psoriatic arthritis in patients with an inadequate response to conventional synthetic disease-modifying antirheumatic drugs
Vibeke Strand,Kurt de Vlam,Jose A Covarrubias-Cobos,Philip J Mease,Dafna D Gladman,Daniela Graham,Cunshan Wang,Joseph C Cappelleri,Thijs Hendrikx,Ming-Ann Hsu
RMD Open.2019;5(1)e000806
2Validation of the cognitive stimulation therapy (CST) program for people with dementia in Portugal
G. Alvares-Pereira,M. V. Silva-Nunes,A. Spector
Aging & Mental Health.2021;25(6)1019
3Effect of tofacitinib on patient-reported outcomes in patients with active psoriatic arthritis and an inadequate response to tumour necrosis factor inhibitors in the phase III, randomised controlled trial: OPAL Beyond
Vibeke Strand,Kurt de Vlam,Jose A Covarrubias-Cobos,Philip J Mease,Dafna D Gladman,Linda Chen,Elizabeth Kudlacz,Joseph Wu,Joseph C Cappelleri,Thijs Hendrikx,Ming-Ann Hsu
RMD Open.2019;5(1)e000808
4Novel Mineral–Vitamin Treatment for Reduction in Cigarette Smoking: A Fully Blinded Randomized Placebo-Controlled Trial
Phillipa K Reihana,Neville M Blampied,Julia J Rucklidge
Nicotine & Tobacco Research.2019;21(11)1496
5Results of studying the clinical efficacy and safety of tofacitinib in the treatment of psoriatic arthritis
T. V. Korotaeva,E. Yu. Loginova
Modern Rheumatology Journal.2019;13(2)112

Subscribe this journal
Submit articles
Most popular articles
Joiu us as a reviewer
Email alerts
Recommend this journal